ERBB2 and breast cancer: In addition, and rather unexpectedly, patients in the SLNB only group had similar OS to those in the SLNB with complete ALND group who had HER2-enriched (HR=1.58, 95% CI: 0.81-3.07, P=0.19) or Triple negative (HR=1.18, 95% CI: 0.76-1.81, P=0.46) breast cancers (Figures 5C, D).